Moderna said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ...
The European Patent Office last week upheld one of Moderna’s key patents, handing the biotech an important victory in its ...
Moderna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said ...
After Moderna last year suffered a loss in its heated patent fight against Pfizer and BioNTech, the mRNA drugmaker can now celebrate a win. The European Patent Office (EPO) has opted to maintain ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 ...
The OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Moderna said on May 17 that the European Patent Office had upheld the validity of one of the company’s key patents, a win in an ongoing Covid-19 vaccine dispute with Pfizer and BioNTech.
Moderna said that the European Patent Office had decided to maintain the validity of one of the company's key patents ...
Moderna MRNA-Q said on Friday the European Patent Office had upheld the validity of one of the company’s key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer PFE-N and BioNTech ...
London: Moderna announced on Friday that it has emerged victorious in a case at the European Patent Office against Pfizer and ...